Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM-101PX in Birch Pollen Allergic Rhinitis or Rhinoconjunctivitis
NCT07254871Phase 2Completed
- Sponsor
- Desentum
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Hydrogel Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in birch pollen allergy comparing DM-101PX with Placebo (2 arms). Primary endpoint: Total Nasal Symptom Score. Started Sep 2025; status: completed.
02
Drugs
DM-101
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT07254871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254871.